OTR3 has a strong pipeline that
relies on the considerable potential 
of the RGTA® technology

liseret1
liseret2

01

Our Pipeline

01

Our Pipeline

Pipeline_2020
Pipeline_2020_Mobile
logo_o

OTR3 focuses on high potential programs
including some award winning key projects.

02

Our R&D
Projects

02

Our R&D
Projects

OTR3 focuses on key development projects with high potential, with the aim of exploiting the versatility of the RGTA® technology to provide to patients new healthcare products that really matter.

The following development programs, relying on the regenerating potential of RGTA® molecules,  are just only a fraction of the technology’s potential, and are to date the closer to market.

The excellence and potential of OTR3’s Pipeline has been confirmed by awards and grants (H2020 SME Instrument, Medicen Label, ANR grant)

Ischemic stroke

RGTA® treatment aims at improving functional recovery by neuronal protection

Alzheimer Disease

Helping patients by blocking Tau protein propagation and protecting neuronal environment

Epidermolysis bullosa

A new therapeutic solution for skin wound healing and associated pain reduction

ARDS

Reducing the severeness and sequels of acute respiratory distress syndrome

liseret1
liseret2
Home
Home

© 2020 – OTR3 – All rights reserved
Design + Development by Popcorn 66

ADDRESS

4, rue Française
75001 Paris, France

© 2020 – OTR3 – All rights reserved
Design + Development by Popcorn 66

OTR3 has a strong pipeline that
relies on the considerable potential 
of the RGTA® technology

liseret1
liseret2

01

Our Pipeline

01

Our Pipeline

Pipeline_2020
Pipeline_2020_Mobile
logo_o

OTR3 focuses on high potential programs
including some award winning key projects.

02

Our R&D
Projects

02

Our R&D
Projects

OTR3 focuses on key development projects with high potential, with the aim of exploiting the versatility of the RGTA® technology to provide to patients new healthcare products that really matter.

The following development programs, relying on the regenerating potential of RGTA® molecules,  are just only a fraction of the technology’s potential, and are to date the closer to market.

The excellence and potential of OTR3’s Pipeline has been confirmed by awards and grants (H2020 SME Instrument, Medicen Label, ANR grant)

Ischemic stroke

RGTA® treatment aims at improving functional recovery by neuronal protection

Alzheimer Disease

Helping patients by blocking Tau protein propagation and protecting neuronal environment

Epidermolysis bullosa

A new therapeutic solution for skin wound healing and associated pain reduction

ARDS

Reducing the severeness and sequels of acute respiratory distress syndrome

liseret1
liseret2
Home
Home

© 2020 – OTR3 – All rights reserved
Design + Development by Popcorn 66

ADDRESS

4, rue Française
75001 Paris, France

© 2020 – OTR3 – All rights reserved
Design + Development by Popcorn 66